ArticleBMC nephrology2025
Increased serum uric acid-to-urinary urate excretion ratio with the kidney function decline in male CKD patients without diabetes: a retrospective cohort study.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe relationship between uric acid and chronic kidney disease (CKD) progression remains unclear. To study the association between the serum uric acid-to-24-hour-urinary urate excretion ratio (SUER) and kidney events in patients experiencing chronic kidney disease (CKD) progression.
methodsA retrospective cohort study involving 165 CKD patients with estimated glomerular filtration rates (eGFRs) between 15 and 150 mL/min/1.73 m
resultsThe general population aged 56.45 ± 15.76 years, and of which 65 (39.39%) CKD patients are females. The SUER was not the risk of experiencing renal endpoint events in the overall population (OR = 1.05; 95% CI: 0.680, 1.621; P = 0.826), but was an associated factor of renal endpoint events in males without diabetes (OR = 2.196; 95%CI:1.191,4.052; P = 0.012).
conclusionsAn increased SUER may be an indicator for kidney function decline in male CKD patients without diabetes. Further studies should focus on subgroup analyses of CKD patients particularly in male CKD patients without diabetes to evaluate whether uric acid-lowering measures are warranted. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.